Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalent Shigella dysentery conjugate vaccine Phase II trial in Chinese infants and children
CTR20181679Phase 2Completed
- Sponsor
- Beijing Luzhu Biotechnology
- Start
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bivalent Shigella (Flexneri 2a + Sonnei) conjugate vaccine in Shigella flexneri infection, Shigella sonnei infection, shigellosis, sponsored by Beijing Luzhu Biotechnology. Started Jan 2019; status: completed.
02
Drugs
bivalent Shigella (Flexneri 2a + Sonnei) conjugate vaccine
03
Conditions
Shigella flexneri infectionShigella sonnei infectionshigellosis
Beyond the preview
Go deeper on CTR20181679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181679.